Aldeyra Therapeutics (ALDX) Treasury Shares (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Treasury Shares of $89808.0 for Q1 2026, down 67.28% on a QoQ basis from $274496.0 in Q4 2025, and down 77.03% year-over-year from $391023.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Treasury Shares (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Treasury Shares history runs 13 years deep, the most recent figure standing at $89808.0 for Q1 2026.
- Quarterly Treasury Shares fell 77.03% year-over-year to $89808.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89808.0 (down 77.03% YoY) and the FY2025 annual result came in at $274496.0, down 49.26% from the prior year.
- Treasury Shares was $89808.0 for Q1 2026 at Aldeyra Therapeutics, down from $274496.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $1.2 million in Q1 2023 and bottomed at $89808.0 in Q1 2026.
- A 5-year average of $706455.0 and a median of $706446.0 in 2022 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2022 — Treasury Shares soared 136.33% — and 2026, when it tumbled 77.03%.
- Aldeyra Therapeutics' Treasury Shares stood at $1.2 million in 2022, then dropped by 20.27% to $944497.0 in 2023, then slumped by 42.72% to $540965.0 in 2024, then sank by 49.26% to $274496.0 in 2025, then tumbled by 67.28% to $89808.0 in 2026.
- Business Quant data shows ALDX's Treasury Shares at $89808.0 in Q1 2026, $274496.0 in Q4 2025, and $281273.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 19.41 Bn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | - |
| 10 | Aldeyra Therapeutics | 94.70 Mn | 94.70 Mn | - | 89,808.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89,808.00 |
| Mar 31, 2026 | 89,808.00 |
| Dec 31, 2025 | 274,496.00 |
| Dec 31, 2025 | 274,496.00 |
| Sep 30, 2025 | 281,273.00 |
| Sep 30, 2025 | 281,273.00 |
| Jun 30, 2025 | 364,567.00 |
| Jun 30, 2025 | 364,567.00 |
| Mar 31, 2025 | 391,023.00 |
| Mar 31, 2025 | 391,023.00 |
| Dec 31, 2024 | 540,965.00 |
| Dec 31, 2024 | 540,965.00 |
| Sep 30, 2024 | 604,009.00 |
| Sep 30, 2024 | 604,009.00 |
| Jun 30, 2024 | 732,056.00 |
| Jun 30, 2024 | 732,056.00 |
| Mar 31, 2024 | 732,056.00 |
| Mar 31, 2024 | 732,056.00 |
| Dec 31, 2023 | 944,497.00 |
| Dec 31, 2023 | 944,497.00 |